Protein conjugate polysaccharide vaccines: challenges in development and global implementation.

Authors: Nair M,
Address: Centre of Excellence - CARRS Indian Institute of Public Health, New Delhi, India, Department of Public Health, University of Oxford, United Kingdom.
Journal: Indian J Community Med.


Publication: 2012 Apr;37(2):79-82. doi: 10.4103/0970-0218.96085.

abstract

Pneumonia and meningitis caused by Haemophilus influenzae type b, Streptococcus pneumoniae, and Neisseria meningitidis are among the leading causes of under five mortality and morbidity. polysaccharide vaccines to prevent these infections are available since 1980s, but these are not effective in infants and children who are the common targets; therefore, Protein conjugated were developed. The aim of this article is to understand the need for peumococcal protein conjugate vaccines, the challenges related to their development and global implementation, and the impact of these vaccines on global child health. Challenges in development of new vaccines are as follows:While pneumonia is a major threat in developing countries, available vaccine 7-valent pneumococcal conjugate vaccine (PCV7) protects against only 30% of invasive disease.Serogroup B of Neisseria meningitidis causes 32% of the cases in the USA and 45-80% or more in Europe. Due to similarity of its capsular polysaccharide with the cell surface glycoprotein on fetal brain tissue, developing a vaccine against this bacterium remains a challenge.Challenges in implementation are as follows:Replacement by nonvaccine serotypes;capsule switching;time duration of the antibody protective effect following vaccination;costs of the vaccines, programme costs, lack of knowledge of the disease burden, and targeting population groups for vaccination.



Related Articles
Review Pneumococcal conjugate vaccine for young children.
Manag Care. 2000
Review Pneumococcal conjugate vaccine for young children.
Selman S, Hayes D, Perin LA, Hayes WS. Manag Care. 2000 Sep; 9(9):49-52, 54, 56-7 passim.
Review Pneumococcal conjugate vaccine (Prevnar; PNCRM7): a review of its use in the prevention of Streptococcus pneumoniae infection.
Paediatr Drugs. 2002
Review Pneumococcal conjugate vaccine (Prevnar; PNCRM7): a review of its use in the prevention of Streptococcus pneumoniae infection.
Darkes MJ, Plosker GL. Paediatr Drugs. 2002; 4(9):609-30.
The future of pneumococcal disease prevention.
Vaccine. 2011
The future of pneumococcal disease prevention.
Rodgers GL, Klugman KP. Vaccine. 2011 Sep 14; 29 Suppl 3:C43-8.
Review Prevention of pneumococcal diseases in the post-seven valent vaccine era: a European perspective.
BMC Infect Dis. 2012
Review Prevention of pneumococcal diseases in the post-seven valent vaccine era: a European perspective.
Weil-Olivier C, van der Linden M, de Schutter I, Dagan R, Mantovani L. BMC Infect Dis. 2012 Sep 7; 12:207. Epub 2012 Sep 7.
[Pneumococcal conjugate vaccine in children].
Rev Med Brux. 2004
[Pneumococcal conjugate vaccine in children].
Lévy J, Swennen B. Rev Med Brux. 2004 Sep; 25(4):A219-22.

To top Home


Show map | Diseases | Vaccination | Chronic disease | Medicine | Pregnancy | Heat & Sunburn | Cold | Security | Useful tips | Faq | News

TraveldoctorOnline 2001 • Disclaimer webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.